HUP0401808A2 - Dosage forms, devices and methods of treatment - Google Patents

Dosage forms, devices and methods of treatment

Info

Publication number
HUP0401808A2
HUP0401808A2 HU0401808A HUP0401808A HUP0401808A2 HU P0401808 A2 HUP0401808 A2 HU P0401808A2 HU 0401808 A HU0401808 A HU 0401808A HU P0401808 A HUP0401808 A HU P0401808A HU P0401808 A2 HUP0401808 A2 HU P0401808A2
Authority
HU
Hungary
Prior art keywords
rumen
amounts
predetermined
ruminant
active substance
Prior art date
Application number
HU0401808A
Other languages
Hungarian (hu)
Inventor
Lionel Barry Lowe
Joseph Raymond Winkle
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3832213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0401808(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP0401808A2 publication Critical patent/HUP0401808A2/en
Publication of HUP0401808A3 publication Critical patent/HUP0401808A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0068Rumen, e.g. rumen bolus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A jelen találmány kérődző állatok bendőjébe való inzertáláshoz és abendőben tartáshoz adaptált szabályozott dózisfelszabadítású elemmelkapcsolatos. Az elem a következőket tartalmazza: a) legalább egy elsőaktív anyagot tartalmazó legalább egy első készítmény egy vagy többkülönálló és előre meghatározott mennyiségét, ahol a készítményt abendő folyadékokban való olyan sebességgel történő feloldódáshozadaptálták, amelynek során az első készítmény egy vagy több mennyiségeaz első aktív anyag rövid idejű vagy pulzáló epizódokban történőfelszabadulását eredményezi a bendőbe; és b) legalább egy másodikolyan készítmény egy vagy több előre meghatározott mennyiségét,amelyet a bendő folyadékokban való szabályozott felszabaduláshozadaptálnak, ahol az első készítmény egy vagy több mennyiségét azelemen belül egy vagy több előre meghatározott helyen biztosítják amásodik készítmény említett egy vagy több mennyiségéhez képest alegalább első aktív anyag bendőben történő előre meghatározottidőpontokban történő egy vagy több késleltetett felszabadulásához, egyelőre meghatározott hosszabb időszak előtt, alatt vagy után, vagy ezektetszőleges kombinációjában, amit az említett második készítményhatároz meg. A jelen találmány kapcsolatos legalább az első aktívanyag kérődző állat bendőjébe késleltetett módon történő bejuttatásimódszerével is, egy vagy több előre meghatározott időpontban, miutánaz állatnak az aktív anyagot tartalmazó készítményt beadták, és azeljárás magába foglalja a jelen találmány szerinti szabályozott dózisfelszabadítású elem állatnak való beadását. Az első aktív anyagtipikusan egy beteg vagy fertőzött kérődző állat kezelésre, vagybetegségének megelőzésre szolgál, vagy mindkét célból használható,vagy alkalmazható a kérődző állat fiziológiai státuszánakmegváltoztatására. ÓThe present invention relates to a controlled dose release element adapted for insertion into the rumen of ruminant animals and for retention in the rumen. The element comprises: a) one or more discrete and predetermined amounts of at least one first composition containing at least one first active substance, where the composition is adapted to dissolve in adsorbent liquids at a rate during which one or more amounts of the first composition are short-term or results in its release into the rumen in pulsatile episodes; and b) at least one or more predetermined amounts of a second formulation adapted for controlled release in rumen fluids, wherein one or more amounts of the first formulation are provided at one or more predetermined locations within the element in relation to said one or more amounts of the second formulation at least first active for one or more delayed release of a substance in the rumen at predetermined times, before, during or after a predetermined longer period, or in any combination thereof, which is determined by said second composition. The present invention is also related to a method of introducing at least the first active substance into the rumen of a ruminant animal in a delayed manner, at one or more predetermined times after the animal has been administered the composition containing the active substance, and the method includes administering the controlled dose release element according to the present invention to the animal. The first active substance is typically used to treat a sick or infected ruminant, or to prevent its disease, or it can be used for both purposes, or it can be used to change the physiological status of the ruminant. HE

HU0401808A 2001-10-19 2002-10-18 Dosage forms, devices and methods of treatment HUP0401808A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR8390A AUPR839001A0 (en) 2001-10-19 2001-10-19 Dosage form, device and methods of treatment
PCT/AU2002/001426 WO2003033031A1 (en) 2001-10-19 2002-10-18 Dosage form, device and methods of treatment

Publications (2)

Publication Number Publication Date
HUP0401808A2 true HUP0401808A2 (en) 2005-01-28
HUP0401808A3 HUP0401808A3 (en) 2005-11-28

Family

ID=3832213

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401808A HUP0401808A3 (en) 2001-10-19 2002-10-18 Dosage forms, devices and methods of treatment

Country Status (22)

Country Link
US (1) US20050064032A1 (en)
EP (1) EP1448151A4 (en)
JP (1) JP2005510485A (en)
KR (1) KR20050037410A (en)
CN (1) CN1571663A (en)
AR (1) AR037116A1 (en)
AU (5) AUPR839001A0 (en)
BR (1) BR0212975A (en)
CA (1) CA2463674A1 (en)
CR (1) CR7312A (en)
EA (1) EA005778B1 (en)
EC (1) ECSP045063A (en)
HR (1) HRP20040231A2 (en)
HU (1) HUP0401808A3 (en)
IL (1) IL160754A0 (en)
MX (1) MXPA04003679A (en)
NO (1) NO20041941L (en)
NZ (1) NZ531672A (en)
PE (1) PE20030519A1 (en)
PL (1) PL368387A1 (en)
WO (1) WO2003033031A1 (en)
ZA (1) ZA200403743B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRN20030021A1 (en) * 2003-07-21 2005-01-22 Ascor Chimici Srl COMPOSITION OF MATERING INCLUDING PARTICLES CONTAINING CHOLINE CHLORIDE TO BE ADMINISTERED IN RUMINALLY PROTECTED AND POST-RUMINALLY EFFECTIVE FORM.
ITMI20041820A1 (en) * 2004-09-24 2004-12-24 Ascor Chimici Srl COMPOSITION IN MICRO-PELLETS WITH CONTROLLED RELEASE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES, PREPARATION PROCEDURE AND RELATED USE IN THE ZOOTECHNICAL SECTOR.
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
AU2005320547B2 (en) * 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
NZ554260A (en) * 2007-09-30 2010-05-28 Agres Ltd Selenomethionine andor selenocysteine administration to non-human animals to increase selenium content in protein sources
WO2010126857A1 (en) * 2009-04-28 2010-11-04 Wyeth Llc Parasiticidal combinations of macrocyclic lactones and polyether antibiotics
AU2014203209B2 (en) * 2009-07-31 2015-11-26 Boehringer Ingelheim Animal Health USA Inc. Sustained release capsules
ES2752923T3 (en) * 2009-07-31 2020-04-06 Boehringer Ingelheim Animal Health Usa Inc Extended-release capsules
EP2512467A1 (en) * 2009-12-17 2012-10-24 Merial Limited Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles
FR2992219B1 (en) * 2012-06-22 2014-07-11 Aditec Lab COMPOSITION FOR THE TREATMENT OF HYPOCALCAEMIA IN RUMINANTS
EP3164117B1 (en) 2014-07-03 2023-09-06 SpecGx LLC Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
US11065246B2 (en) 2016-02-08 2021-07-20 SpecGx LLC Glucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties
US10737079B2 (en) * 2016-12-02 2020-08-11 Clexio Biosciences Ltd. Gastric residence system
AU2018292285B2 (en) * 2017-06-26 2023-05-25 Boehringer Ingelheim Animal Health USA Inc. Dual active parasiticidal granule compositions, methods and uses thereof
CA189878S (en) 2017-08-25 2021-02-18 Argenta Mfg Limited Intraruminal device
BR112021004458A2 (en) * 2018-09-10 2021-05-25 Argenta Innovation Limited controlled release formulations in delivery devices
BR112021004523A2 (en) * 2018-09-10 2021-06-08 Argenta Innovation Limited formulations for sustained release in administration devices
WO2020068510A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
FI4013348T3 (en) * 2019-08-14 2024-03-15 Elanco Tiergesundheit Ag New wing protector for winged capsule and method of using same
BR112022014865A2 (en) * 2020-02-07 2022-09-20 Elanco Animal Health Incorporated WINGED CAPSULE
WO2021242481A1 (en) * 2020-05-28 2021-12-02 Boehringer Ingelheim Animal Health USA Inc. Bi-modal release intra-ruminal capsule device and methods of use thereof
DK4037666T3 (en) 2020-12-08 2024-06-24 Ruminant Biotech Corp Ltd IMPROVEMENT OF DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO ANIMALS
CN113398337A (en) * 2021-06-23 2021-09-17 上海市肺科医院 Spinal internal fixation device containing artificial bone carrier implanted with antituberculosis drugs in sustained release manner

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU520409B2 (en) * 1977-05-25 1982-01-28 Commonwealth Scientific And Industrial Research Organisation Controlled release composition
GB2077586A (en) * 1980-06-12 1981-12-23 Standard Telephones Cables Ltd Sustained-release device
NZ197543A (en) * 1980-07-02 1984-12-14 Commw Scient Ind Res Org Controlled release compositions for inclusion in intraruminal devices
US4416659A (en) * 1981-11-09 1983-11-22 Eli Lilly And Company Sustained release capsule for ruminants
NZ203203A (en) * 1982-02-16 1985-09-13 Commw Scient Ind Res Org Controlled release device:gas diffusion limited
IE54171B1 (en) * 1982-06-22 1989-07-05 Univ Glasgow Device for introducing nutrients and/or therapeutic materials into ruminant animals
GB8328916D0 (en) * 1983-10-28 1983-11-30 Castex Prod Pharmaceutical pellet
US4777049A (en) * 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
NZ212100A (en) * 1984-06-02 1988-07-28 Castex Prod Rumen bolus; outer casing sheds in segments
US4723958A (en) * 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US4867980A (en) * 1986-10-10 1989-09-19 Coopers Animal Health Australia Limited Heavy density depot
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5938654A (en) * 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US4957494A (en) * 1987-06-25 1990-09-18 Alza Corporation Multi-layer delivery system
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
GB8829089D0 (en) * 1988-12-13 1989-01-25 Coopers Animal Health Intra ruminal device
DE59000232D1 (en) * 1989-02-11 1992-09-10 Bayer Ag MEDICINAL PRODUCTS WITH CONTROLLED DELIVERY OF ACTIVE SUBSTANCES.
US5110598A (en) * 1989-06-30 1992-05-05 Smithkline Beecham Corp. Intermittent release dosage form
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5017381A (en) * 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
MX9200339A (en) * 1991-01-28 1992-08-01 Hoechst Ag PREPARED FOR THE CONTROLLED RELEASE OF ACTIVE SUBSTANCES, WHICH ARE APPROPRIATE AS THERAPEUTICS OR TO IMPROVE THE GROWTH AND USE OF FEED IN RUMINANTS
US5417682A (en) * 1991-01-30 1995-05-23 Alza Corporation Device for administering active agent to biological environment
AU650113B2 (en) * 1991-04-05 1994-06-09 Eli Lilly And Company Sustained release capsule and formulations
US5240713A (en) * 1991-09-27 1993-08-31 Alza Corporation Dual rate agent delivery device
US5221278A (en) * 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
WO1995019763A1 (en) * 1994-01-20 1995-07-27 New Zealand Pastorial Agriculture Research Institute Limited Device for administration of beneficial materials to ruminants
AUPM897594A0 (en) * 1994-10-25 1994-11-17 Daratech Pty Ltd Controlled release container
EP1126826B3 (en) * 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
US6569857B1 (en) * 1999-05-03 2003-05-27 Drugtech Corporation Dietary supplement
DE19956486A1 (en) * 1999-11-24 2001-06-21 Lohmann Therapie Syst Lts Multi-layer preparation for the controlled, pulsed delivery of active ingredients
CA2395892C (en) * 1999-12-31 2014-06-03 Rutgers, The State University Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
AU2001237424A1 (en) * 2000-02-28 2001-09-12 Akzo Nobel N.V. Bodies for the controlled release of active substances

Also Published As

Publication number Publication date
IL160754A0 (en) 2004-08-31
MXPA04003679A (en) 2004-07-23
AU2009250987A1 (en) 2010-01-14
CA2463674A1 (en) 2003-04-24
US20050064032A1 (en) 2005-03-24
PE20030519A1 (en) 2003-06-13
AU2002332975B2 (en) 2005-02-03
EP1448151A4 (en) 2010-01-13
KR20050037410A (en) 2005-04-21
AU2004210542B9 (en) 2005-09-01
HRP20040231A2 (en) 2004-08-31
NZ531672A (en) 2006-08-31
CN1571663A (en) 2005-01-26
AUPR839001A0 (en) 2001-11-15
PL368387A1 (en) 2005-03-21
AU2004210542B2 (en) 2005-07-28
HUP0401808A3 (en) 2005-11-28
AU2002332975B9 (en) 2005-03-17
BR0212975A (en) 2004-10-13
AU2005227413A1 (en) 2005-11-17
EP1448151A1 (en) 2004-08-25
AU2002332975C1 (en) 2009-01-29
AU2004210542C1 (en) 2009-01-08
CR7312A (en) 2004-10-27
EA005778B1 (en) 2005-06-30
AU2004210542A1 (en) 2004-09-30
JP2005510485A (en) 2005-04-21
ECSP045063A (en) 2004-05-28
AR037116A1 (en) 2004-10-20
WO2003033031A1 (en) 2003-04-24
ZA200403743B (en) 2005-05-16
NO20041941L (en) 2004-05-10
EA200400557A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
HUP0401808A2 (en) Dosage forms, devices and methods of treatment
Parisi et al. Recurrent intraoral pyogenic granuloma with satellitosis treated with corticosteroids
RU95109905A (en) Liquid, semisolid, solid, gel-like or paste-like compositions and a method of mouth cavity disease treatment
DK0759757T3 (en) Oral, liquid alendronate formulations
Godfrey et al. A randomized clinical trial on the treatment of oral herpes with topical zinc oxide/glycine
CY1115766T1 (en) CLEANING AND STABILIZATION OF Peptide and Protein in Pharmaceutical Agents
HUP0102899A2 (en) Process for preparation of compositions for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
BRPI0513200A (en) use of an anti-igf-1r antibody in the preparation of a medicament for combined treatment for nonhematological malignancies
AR045956A1 (en) MULTIPARTICLES OF PANTOPRAZOL AND FORMULATION CONTAINING THEM
McComas et al. Increasing compliance with medical procedures: Application of the high‐probability request procedure to a toddler
DE69116380D1 (en) PHARMACEUTICAL PREPARATION FOR TREATING EXTENDED COAGLING TIME
FI3749308T3 (en) Treatment of patients with classic fabry disease with migalastat
Park et al. Modified titanium implant as a gateway to the human body: the implant mediated drug delivery system
Nishikawa et al. Healing of digital dermatitis after a single treatment with topical oxytetracycline in 89 dairy cows
Borges et al. Calcitonin: a non-invasive giant cells therapy
Jorgensen et al. The ins and outs of periodontal antimicrobial therapy
RU2297233C1 (en) Method for treating glossalgia cases
Stefos et al. Managing vomiting in the third trimester of pregnancy during fixed prosthodontic treatment. A case report and review of the literature
DE68916651D1 (en) MEDICINES FOR TREATING TOXOPLASMOSIS.
Van Dyck et al. Nutrition in the ICU: sometimes route does matter
ATE107504T1 (en) MEDICATIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS.
JPS6411619B2 (en)
FR2786699B1 (en) MEDICINE, IN PARTICULAR FOR PREVENTING OR TREATING SEXUAL DYSFUNCTIONS
Rubinstein Postprandial drowsiness
Rout et al. Advances in Local Anesthesia and Pain Management for Practicing Dentists: A Comprehensive Review

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees